A new phase 3 clinical trial called HOPE-3 has brought encouraging results for the Duchenne community. Results of this phase three trial was presented at the American Society of Gene and Cell Therapy Conference on May 11-15, 2026, in Boston Massachusetts. The trial focused on deramiocel, an investigational cell therapy developed by Capricor Therapeutics.
Cell therapy is a treatment that transfers a specific cell type, or in some cases multiple types of cells, to treat or prevent a disease. Deramiocel uses allogeneic (meaning donated) cells from cardiac tissue.
Overall, 106 boys and young men aged 10 and older living with Duchenne muscular dystrophy (DMD) participated in this trial. As part of the study, they received either deramiocel or a placebo every three months by intravenous infusion. Those who received deramiocel showed meaningful improvements in upper limb function compared to those who received placebo (non-medicinal treatment). The therapy also showed positive effects on heart function, including a measurable improvement in how well the heart pumps blood, and a reduction in the progression of cardiac fibrosis, a serious complication for people living with Duchenne as they get older.
Importantly, no safety concerns emerged. There was no difference in serious side effects between the treatment and placebo groups.
Deramiocel is currently under review by the U.S. Food and Drug Administration (FDA), with a decision expected as early as August 22, 2026. This trial’s results played a direct role in advancing that review. If approved, this drug would be a first in kind to target both skeletal muscle and cardiac muscle function in later-stage of disease.
For Canadian families, this milestone carries real weight. If approved in the United States, it strengthens the case for timely access to deramiocel here in Canada, where over 800 boys and young men are living with Duchenne today. Defeat Duchenne Canada continues to advocate for equitable and affordable access to emerging treatments so that every Canadian family has the same opportunity to benefit from scientific progress, no matter where they live.
Please see the press release shared by Capricor Therapeutics for more details.
Want to know more about Duchenne Research?
Scientists and medical experts have been tirelessly pursuing diverse approaches to defeat Duchenne muscular dystrophy. From tackling the root cause to alleviating symptoms, the field of research is vast and promising. Explore the various strategies being developed and tested, and gain insights into the future of muscular dystrophy treatment: